



FOOD AND DRUG ADMINISTRATION

Grant Number: 5U18FD004610-03 REVISED
FAIN: U18FD004610

Principal Investigator:
Mary Glassburner

Project Title: Rapid Response Teams for Food Protection

Mr. Fischer, Bret
Director, Division of Administration
920 Wildwood Drive
PO Box 570
Jefferson City, MO 651020570

Award e-mailed to: grants@health.mo.gov

Budget Period: 09/01/2014 – 08/31/2015
Project Period: 09/01/2012 – 08/31/2015

Dear Business Official:

The Food and Drug Administration hereby revises this award to reflect a decrease in the amount of \$52,885 (see "Award Calculation" in Section I and "Terms and Conditions" in Section III) to MISSOURI STATE DEPT/ HEALTH & SENIOR SRV in support of the above referenced project. This award is pursuant to the authority of PHS Act, Sec 1706, 42 USC 300u-5, as amended; Sec 2(d), PL 98-551 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award including the "Terms and Conditions" is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

If you have any questions about this award, please contact the Grants Management Specialist and the Project Officer listed in the terms and conditions.

Sincerely yours,

Kimberly Pendleton
Grants Management Officer
Office of Acquisitions & Grants Services
Division of Acquisition Support and Grants
Grants & Assistance Team
FOOD AND DRUG ADMINISTRATION

See additional information below

SECTION I – AWARD DATA – 5U18FD004610-03 REVISED**Award Calculation (U.S. Dollars)**

Salaries and Wages	\$129,464
Fringe Benefits	\$63,615
Personnel Costs (Subtotal)	\$193,079
Supplies	\$9,030
Travel Costs	\$23,678
Other Costs	\$34,399
Consortium/Contractual Cost	\$36,515

Federal Direct Costs	\$296,701
Federal F&A Costs	\$37,072
Approved Budget	\$333,773
Federal Share	\$333,773
Less Unobligated Balance	\$86,658
TOTAL FEDERAL AWARD AMOUNT	\$247,115

AMOUNT OF THIS ACTION (FEDERAL SHARE) (\$-52,885)

SUMMARY TOTALS FOR ALL YEARS		
YR	THIS AWARD	CUMULATIVE TOTALS
3	\$247,115	\$247,115

* Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project.

Fiscal Information:

CFDA Number: 93.103

EIN: [REDACTED]

Document Number: UFD004610A

Fiscal Year: 2014

IC	CAN	2014
FD	6990928	\$247,115

* Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project.

FDA Administrative Data:

PCC: ORA7 / OC: 414P / Processed: FDAKPU 03/18/2016

SECTION II – PAYMENT/HOTLINE INFORMATION – 5U18FD004610-03 REVISED

Grant payments will be made available through the DHHS Payment Management System (PMS). PMS is administered by the Division of Payment Management, Program Support Center (PSC), DHHS, Office of the Deputy Assistant Secretary, Finance. Requests for downloadable forms and inquiries regarding payment should be directed to:

Regular Mailing Address:
Division of Payment Management
P.O. Box 6021
Rockville, MD 20852

Telephone: (301) 443-1660

Included are the following Links & Instructions for drawing down funds, reporting expenditures, required forms, and the help desk info:

Homepage: <http://www.dpm.psc.gov/Default.aspx>

Grant Recipient Information:

http://www.dpm.psc.gov/grant_recipient/grant_recipient.aspx?explorer.event=true

Grant Recipient Forms:

http://www.dpm.psc.gov/grant_recipient/grantee_forms.aspx?explorer.event=true

PMS Help Desk: <http://www.dpm.psc.gov/help/help.aspx?explorer.event=true>

The ONE-DHHS Help Desk for PMS Support is now available Monday – Friday from 7 a.m. to 9 p.m. EST (except Federal Holidays). Phone (877) 614-5533; Email PMSSupport@psc.gov

SECTION III – TERMS AND CONDITIONS – 5U18FD004610-03 REVISED

This award is based on the application submitted to, and as approved by, FDA on the above-title project and is subject to the terms and conditions incorporated either directly or by reference in the following:

- a. The grant program legislation and program regulation cited in this Notice of Grant Award.
- b. The restrictions on the expenditure of federal funds in appropriations acts to the extent those restrictions are pertinent to the award.
- c. 45 CFR Part 75.
- d. The HHS Grants Policy Statement, including addenda in effect as of the beginning date of the budget period.
- e. Federal Award Performance Goals: As required by the periodic report in the RPPR or in the final progress report when applicable.
- f. A required Federal Financial Report (FFR) SF-425 must be submitted annually. FDA now requires all annual financial expenditure reports to be submitted electronically using the Federal Financial Report (FFR) system located in the eRA Commons. Annual FFRs must be submitted for each budget period no later than 90 days after the end of the calendar quarter in which the budget period ended. The reporting period for an annual FFR will be that of the budget period for the particular grant; however, the actual submission date is based on the calendar quarter. Failure to submit timely reports may affect future funding
- g. Closeout Requirements (when applicable): A Final Program Progress Activity Report, Final Federal Financial Report SF-425, Final Invention Statement HHS-568 (if applicable), Tangible Personal Property Report SF-428, and Statement of Disposition of Equipment (if applicable) must be submitted within 90 days after the expiration date of the project period.
- h. This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

This award has been assigned the Federal Award Identification Number (FAIN) U18FD004610. Recipients must document the assigned FAIN on each consortium/subaward issued under this award.

Treatment of Program Income:

Additional Costs

SECTION IV – FD Special Terms and Condition – 5U18FD004610-03 REVISED

STANDARD TERMS AND CONDITIONS - RAPID RESPONSE TEAMS (RRT)

3/16/2016 - This award is revised to reflect the official closeout of this grant and the deobligation \$52,884.03 as stated on the Federal Financial (FFR) Report.

12/31/2014 - This award is revised to reflect an approved carryover amount as submitted by the grantee in year -03. The carryover amount is \$86,658.

ALL PREVIOUS TERMS AND CONDITIONS REMAIN IN EFFECT.

GRANTS POLICY STATEMENT (GPS)

This award is subject to the requirements of the HHS Grants Policy Statement (HHS GPS <http://dhhs.gov/asfr/ogapa/grantinformation/hhsggps107.pdf>) that are applicable to you based on your recipient type and the purpose of this award. This includes any requirements in Parts I and II of the HHS GPS that apply to an award.

Although consistent with the HHS GPS, any applicable statutory or regulatory requirements, including 45 CFR parts 74 or 92, directly apply to this award apart from any coverage in the HHS GPS. (Please note as of October 1, 2006, the HHS Grants Policy Statement (GPS) supersedes in its entirety the above cited PHS GPS, dated April 1, 1994, and addendum dated January 24, 1995).

REPORTING REQUIREMENTS:

TWO (2) PROGRESS ACTIVITY-REPORTS ARE REQUIRED WITHIN THE BUDGET PERIOD:

1) A mid-year progress report covering six months of grant activity is required for each funded year. For mid-year progress reports in a continuation year (i.e. not the first year of the cooperative agreement), grantees should include a summary of accomplishments (including achievement of milestones/benchmarks as listed in the RFA) made between the previous year's annual progress report due date and the end of the previous year's budget period. This is to confirm that progress projected in the previous year's annual progress report was in fact achieved.

2) A year-end report (PHS-2590) will be required no later than (60) days prior to the end of the current budget period. This report will be due each funded year. These reports must contain the following information:

A. General progress of the Rapid Response Teams Cooperative Agreement project.

B. Project status in relation to established timeline (i.e. milestones and benchmarks as noted in the Program Announcement). For annual progress reports during a continuation year (i.e. not the last year of the cooperative agreement), grantees should include a projection of accomplishments (including achievement of milestones/benchmarks as listed in the RFA) to be made between the annual progress report due date and the end of the budget period. Reports will be approved based on those projections.

C. Rapid Response Teams Cooperative Agreement project ?point of contact? (POC) to include mailing address, telephone number, and e-mail address.

D. Funding expended and funds remaining for the Rapid Response Teams Cooperative Agreement.

NOTE ON CLOSEOUT REQUIREMENT AT THE END OF THE PROJECT PERIOD:

Within ninety (90) days of the end of the grants project period submit the following documents:

1. A Final Program Progress Activity Report;

2. A Final Financial Status Report (FSR) http://grants.nih.gov/grants/fsr_sf269_long.pdf.

3. Invention Statement (available at <http://grants.nih.gov/grants/hhs568.pdf>) These documents must be submitted to the FDA Grants Management Officer no later than ninety (90) days after the expiration date of the project period.

4. Statement of Disposition of Equipment (if applicable) must be submitted within 90 days after the expiration date of the project period.

All forms can be found at: <http://grants.nih.gov/grants/forms.htm>.

5. The Final Program Progress activity-report must contain the following information:

A. Summary of results in relation to specific aims of the Rapid Response Teams Cooperative Agreement project.

B. Full written documentation of the Rapid Response Teams Cooperative Agreement project.

C. Copies of any results as described in the Rapid Response Teams Cooperative Agreement grant application.

D. Analysis and evaluation of the Rapid Response Teams Cooperative Agreement results.

The documentation must be in a clear format and contain sufficient detail so that other State and Local Food Safety Regulatory Agencies could utilize the final project report as a model for similar work in their respective state.

(If applicable) All Non-competing Continuation Applications (Type 5s) for future years of support are due to the Grants Management Office two (2) months prior to the next budget period start date. The continuation application is the PHS-2590 FORM (which in itself is referred to as the ?Progress Report?) and is found within this link:

<http://grants.nih.gov/grants/guide/notice-files/NOT-OD-09-139.html>

Annual Financial Status Reports (SF-269) are required and must be submitted to the FDA Grants Management Officer within ninety (90) days after the end of the budget period, available at http://grants.nih.gov/grants/fsr_sf269_long.pdf. Grantees must also submit in conjunction with the SF-269 a detailed breakdown of expenditures per budget category (personnel, equipment, supplies, etc.). This can be submitted in the format most convenient for the grantee, but must contain enough information for OP/OAGS to determine what was actually purchased/funded using cooperative agreement funds.

All of the above should be e-mailed to:

Jennerfer Torres-Hernandez; Grants Management Specialist
Food and Drug Administration, OAGS/DASG
5630 Fishers Lane, Rm. 2036, HFA 500
Rockville, MD 20857
Telephone: 240-402-7683; E-mail: Jennerfer.Torres-Hernandez@fda.hhs.gov

AND

Travis Goodman; Project Officer
Food and Drug Administration
Telephone: 317-226-6500 X108 ; E-mail: travis.goodman@fda.hhs.gov

AND

Lauren Yeung
Food and Drug Administration
Telephone: 301-796-6623; E-mail: Lauren.Yeung@fda.hhs.gov

SPECIAL TERMS AND CONDITIONS - RRT COOPERATIVE AGREEMENT SUBSTANTIAL INVOLVEMENT:

Periodic Rapid Response Teams Cooperative Agreement program monitoring will be conducted which may be in the form of telephone conversations, correspondence, e-mail transmissions, etc., between the Principal Investigator and the Project Officer/Grants Management Officer/Grants Management Specialist. Program monitoring may also be in the form of site visits.

Substantive involvement by the awarding agency is inherent in the cooperative agreement award. Accordingly, the FDA will have substantial involvement in the program funded by the cooperative agreement. Substantive involvement includes, but is not limited to, the following:

A. The FDA will have prior approval of the appointment of all key administrative and scientific personnel proposed by the grantee.

B. The FDA will be directly involved in the guidance and development of the program.

C. The FDA scientists will participate, with the grantee, in determining and carrying out scientific and technical activities. Collaboration will also include data analysis, interpretation of findings, and, where appropriate, co-authorship of publications.

Principal Investigator and the Project Officer/Grants Management Officer/Grants Management Specialist. Program monitoring may also be in the form of site visits.

Substantive involvement by the awarding agency is inherent in the cooperative agreement award. Accordingly, the FDA will have substantial involvement in the program funded by the cooperative agreement. Substantive involvement includes, but is not limited to, the following:

A. The FDA will have prior approval of the appointment of all key administrative and scientific personnel proposed by the grantee.

B. The FDA will be directly involved in the guidance and development of the program.

C. The FDA scientists will participate, with the grantee, in determining and carrying out scientific and technical activities. Collaboration will also include data analysis, interpretation of findings, and, where appropriate, co-authorship of publications.

Modification of milestones from the RFA: Please refer to 2014-2015 grant RRT Program Workgroup in FoodSHIELD

A minimum of two key personnel must attend the annual RRT Face to Face Meeting as a condition of the award. The grantee should budget accordingly to cover all travel costs with RRT cooperative agreement funds.

A rebudgeting request covers reallocation of cooperative agreement funds and change of planned expenditures (compared to the existing budget on record for the grantee) either between budget categories (personnel, equipment, supplies, etc.) or within a single budget category. All rebudgeting requests that involve moving cooperative agreement funds between budget categories must be submitted and approved by OP/OAGS. A new NGA will only be issued when rebudgeting requests reach a cumulative total (during a single budget period) of 25% of the total award or more. Rebudgeting requests within a single budget category must be submitted and approved by OP/OAGS when they reach a cumulative (during a single budget period) total of \$10,000 or more.

FUNDING RESTRICTIONS:

These cooperative agreements are not to fund licensed medicated feed or routine feed safety GMP or BSE inspections, or retail food or foodservice inspections that are unrelated to the food manufacturing, processing, wholesaling, transportation or warehousing of manufactured foods or are currently covered under a FDA Food safety contract. These awards may be only used for the development of new State rapid response teams and to enhance and supplement existing State food protection infrastructure. States with current FDA food inspection contracts can maintain these contracts for food inspections at the discretion of the State and FDA. However, the facilities, staff costs, travel and other costs and work covered under the contract cannot be

counted towards fulfillment of the cooperative agreement and must remain distinct and separate from the cooperative agreement. The State must be able to account for expenditure of funds from the contract and cooperative agreement separately.

PROGRAM INCOME

1. Grantees are required to report any Program Income generated during the Project Period of this grant. Except for royalty income generated from patents and inventions, the amount and disposition of Program Income must be identified on lines 10(q), (r), (s), and (t) of the grantees Financial Status Report (FSR) @

http://grants.nih.gov/grants/fsr_sf269_long.pdf

2. Examples of Program Income include (and not limited to): fees for services performed during the grant or sub-grant period, proceeds from sale of tangible personal or real property, usage or rental fees, patent or copyright royalties, and proceeds from the sale of products and technology developed under the grant.

3. Any Program Income generated during the Project Period of this grant by the grantee or sub-grantee is subject to the Addition Alternative for Program Income and, therefore, must only be used to further the goals of the project for which this grant was awarded.

Failure to comply with the above stated Standard and Special Terms and Conditions could result in the suspension or termination of this grant project.

THE EXPANDED AUTHORITIES DO NOT APPLY TO THIS GRANT

Direct inquiries regarding scientific programmatic issues to the official listed below.

Direct inquiries regarding fiscal and/or administrative matters to the grants management specialist listed below.

All formal correspondence/reports regarding the grant should be signed by an authorized institutional official and the Principal Investigator and should be sent to the attention of the grants management specialist, unless otherwise explicitly directed.

STAFF CONTACTS

Grants Management Specialist: Daniel Lukash

Email: daniel.lukash@fda.hhs.gov **Phone:** 240-402-7596

SPREADSHEET SUMMARY

GRANT NUMBER: 5U18FD004610-03 REVISED

INSTITUTION: MISSOURI STATE DEPT/ HEALTH & SENIOR SRV

Budget	Year 3
Salaries and Wages	\$129,464
Fringe Benefits	\$63,615
Personnel Costs (Subtotal)	\$193,079
Supplies	\$9,030
Travel Costs	\$23,678
Other Costs	\$34,399
Consortium/Contractual Cost	\$36,515
TOTAL FEDERAL DC	\$296,701
TOTAL FEDERAL F&A	\$37,072

TOTAL COST

\$247,115
